ILX-002 / Illexcor Therapeutics - LARVOL DELTA

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease (PRNewswire) - "Zynext Ventures USA LLC...announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD)....Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits....'We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year'."

Licensing / partnership • New trial • Sickle Cell Disease

A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice (ASH 2024) - "The dramatic disease-modifying effects observed in Townes SS mice at clinically achievable drug levels support ILX-002's potential to significantly improve patient outcomes. These compelling preclinical results warrant rapid advancement of ILX-002 into human trials."

Preclinical • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Pain • Sickle Cell Disease